Cargando…

Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors

Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell rena...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Lee E., Nickerson, Michael L., Brennan, Paul, Toro, Jorge R., Jaeger, Erich, Rinsky, Jessica, Han, Summer S., Zaridze, David, Matveev, Vsevolod, Janout, Vladimir, Kollarova, Hellena, Bencko, Vladimir, Navratilova, Marie, Szeszenia-Dabrowska, Neonilia, Mates, Dana, Schmidt, Laura S., Lenz, Petra, Karami, Sara, Linehan, W. Marston, Merino, Maria, Chanock, Stephen, Boffetta, Paolo, Chow, Wong-Ho, Waldman, Frederic M., Rothman, Nathaniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192834/
https://www.ncbi.nlm.nih.gov/pubmed/22022277
http://dx.doi.org/10.1371/journal.pgen.1002312
_version_ 1782213805538803712
author Moore, Lee E.
Nickerson, Michael L.
Brennan, Paul
Toro, Jorge R.
Jaeger, Erich
Rinsky, Jessica
Han, Summer S.
Zaridze, David
Matveev, Vsevolod
Janout, Vladimir
Kollarova, Hellena
Bencko, Vladimir
Navratilova, Marie
Szeszenia-Dabrowska, Neonilia
Mates, Dana
Schmidt, Laura S.
Lenz, Petra
Karami, Sara
Linehan, W. Marston
Merino, Maria
Chanock, Stephen
Boffetta, Paolo
Chow, Wong-Ho
Waldman, Frederic M.
Rothman, Nathaniel
author_facet Moore, Lee E.
Nickerson, Michael L.
Brennan, Paul
Toro, Jorge R.
Jaeger, Erich
Rinsky, Jessica
Han, Summer S.
Zaridze, David
Matveev, Vsevolod
Janout, Vladimir
Kollarova, Hellena
Bencko, Vladimir
Navratilova, Marie
Szeszenia-Dabrowska, Neonilia
Mates, Dana
Schmidt, Laura S.
Lenz, Petra
Karami, Sara
Linehan, W. Marston
Merino, Maria
Chanock, Stephen
Boffetta, Paolo
Chow, Wong-Ho
Waldman, Frederic M.
Rothman, Nathaniel
author_sort Moore, Lee E.
collection PubMed
description Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR = 6.10; 95% CI: 2.28–16.35, p = 3.76E-4, p-global = 8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher proportion of wild-type ccRCC tumors [former: OR = 0.70 (0.20–1.31) and current: OR = 0.56 (0.32–0.99); P-trend = 0.04]. Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical entity from inactivated cases.
format Online
Article
Text
id pubmed-3192834
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31928342011-10-21 Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors Moore, Lee E. Nickerson, Michael L. Brennan, Paul Toro, Jorge R. Jaeger, Erich Rinsky, Jessica Han, Summer S. Zaridze, David Matveev, Vsevolod Janout, Vladimir Kollarova, Hellena Bencko, Vladimir Navratilova, Marie Szeszenia-Dabrowska, Neonilia Mates, Dana Schmidt, Laura S. Lenz, Petra Karami, Sara Linehan, W. Marston Merino, Maria Chanock, Stephen Boffetta, Paolo Chow, Wong-Ho Waldman, Frederic M. Rothman, Nathaniel PLoS Genet Research Article Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR = 6.10; 95% CI: 2.28–16.35, p = 3.76E-4, p-global = 8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher proportion of wild-type ccRCC tumors [former: OR = 0.70 (0.20–1.31) and current: OR = 0.56 (0.32–0.99); P-trend = 0.04]. Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical entity from inactivated cases. Public Library of Science 2011-10-13 /pmc/articles/PMC3192834/ /pubmed/22022277 http://dx.doi.org/10.1371/journal.pgen.1002312 Text en This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Moore, Lee E.
Nickerson, Michael L.
Brennan, Paul
Toro, Jorge R.
Jaeger, Erich
Rinsky, Jessica
Han, Summer S.
Zaridze, David
Matveev, Vsevolod
Janout, Vladimir
Kollarova, Hellena
Bencko, Vladimir
Navratilova, Marie
Szeszenia-Dabrowska, Neonilia
Mates, Dana
Schmidt, Laura S.
Lenz, Petra
Karami, Sara
Linehan, W. Marston
Merino, Maria
Chanock, Stephen
Boffetta, Paolo
Chow, Wong-Ho
Waldman, Frederic M.
Rothman, Nathaniel
Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
title Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
title_full Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
title_fullStr Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
title_full_unstemmed Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
title_short Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
title_sort von hippel-lindau (vhl) inactivation in sporadic clear cell renal cancer: associations with germline vhl polymorphisms and etiologic risk factors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192834/
https://www.ncbi.nlm.nih.gov/pubmed/22022277
http://dx.doi.org/10.1371/journal.pgen.1002312
work_keys_str_mv AT mooreleee vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT nickersonmichaell vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT brennanpaul vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT torojorger vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT jaegererich vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT rinskyjessica vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT hansummers vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT zaridzedavid vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT matveevvsevolod vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT janoutvladimir vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT kollarovahellena vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT benckovladimir vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT navratilovamarie vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT szeszeniadabrowskaneonilia vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT matesdana vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT schmidtlauras vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT lenzpetra vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT karamisara vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT linehanwmarston vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT merinomaria vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT chanockstephen vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT boffettapaolo vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT chowwongho vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT waldmanfredericm vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors
AT rothmannathaniel vonhippellindauvhlinactivationinsporadicclearcellrenalcancerassociationswithgermlinevhlpolymorphismsandetiologicriskfactors